[Experimental study of the "'rebound syndrome" following discontinuation of prolonged phenazepam administration and possibilities for preventing it].
Phenazepam given to rats in a daily dose of 2 mg/kg intraperitoneally for a long (30 days) time ceased to produce the sedative effect, and discontinuation of the medication led to development of the so-called "recoil syndrome" characterized by general depression and disturbances of the conditioned-reflex activity. The "recoil syndrome" was distinguished for a selective specificity, since its motor and sensor manifestations were eliminated only by benzodiazepine derivatives (phenazepam, diazepam). Drugs from other chemical slasses (meprobamate, trioxazine, amipazin) did not influence this syndrome.
D000818:Animals; D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000009:adverse effects* / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D003214:Conditioning, Classical; D003863:Depression / Q000209:etiology; D003975:Diazepam / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008620:Meprobamate / Q000627:therapeutic use; D008702:Methaqualone / Q000031:analogs & derivatives / Q000627:therapeutic use; D009025:Morpholines / Q000627:therapeutic use; D010634:Phenobarbital / Q000627:therapeutic use*; D051381:Rats; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis* / Q000188:drug therapy
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D009025:Morpholines; D001569:Benzodiazepines; C012409:lonetil M3; C005831:trimetozine; C017928:phenazepam; D008702:Methaqualone; D008620:Meprobamate; D003975:Diazepam; D002746:Chlorpromazine; D010634:Phenobarbital
Eksperimental'noe izuchenie "sindroma otdachi" posle prekrascheniia dlitel'nogo vvedeniia fenazepama i vozmozhnosti ego ustraneniia.